Treatment duration of febrile urinary tract infection: A pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women

BMC Medicine

Volumn 15, Issue 1, 2017, Pages

  van Nieuwkoop, Cees ^a,b   van der Starre, Willize E ^b   Stalenhoef, Janneke E ^b   van Aartrijk, Anna M ^b   van der Reijden, Tanny J K ^b   Vollaard, Albert M ^b   Delfos, Nathalie M ^c   van 't Wout, Jan W ^b,d   Blom, Jeanet W ^b   Spelt, Ida C ^e   Leyten, Eliane M S ^d   Koster, Ted ^f   Ablij, Hans C ^g   van der Beek, Martha T ^b   Knol, Mirjam J ^h   van Dissel, Jaap T ^b,h  

^a HAGA HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ALRIJNE HOSPITAL   (Netherlands)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

^e Primary Health Care Center   (Netherlands)

^f GROENE HART HOSPITAL   (Netherlands)

^g Alrijne Hospital   (Netherlands)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Antibiotic therapy; Pyelonephritis; Treatment duration; Urinary tract infection

Indexed keywords

CIPROFLOXACIN; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUTCHMAN; FEBRILE URINARY TRACT INFECTION; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; TREATMENT DURATION; URINARY TRACT INFECTION; URINE CULTURE; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; MIDDLE AGED; NETHERLANDS; TIME FACTOR; URINARY TRACT INFECTIONS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PLACEBOS; TIME FACTORS; URINARY TRACT INFECTIONS;

EID: 85016648739     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-017-0835-3     Document Type: Article

References (23)

1. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677-84.
2. Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ. 2010;340:c2115.
3. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Investig. 2014;124(10):4212-8.
4. Spellberg B. The New Antibiotic Mantra - "Shorter Is Better". JAMA Int Med. 2016;176(9):1254-5.
5. Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2013;68(10):2183-91.
6. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-120.
7. van der Starre WE, van Dissel JT, van Nieuwkoop C. Treatment duration of febrile urinary tract infections. Curr Infect Dis Rep. 2011;13(6):571-8.
8. Sandberg T, Skoog G, Hermansson AB, Kahlmeter G, Kuylenstierna N, Lannergard A, Otto G, Settergren B, Ekman GS. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012;380(9840):484-90.
9. van Nieuwkoop C, van't Wout JW, Assendelft WJ, Elzevier HW, Leyten EM, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Kuijper EJ, et al. Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). BMC Infect Dis. 2009;9:131.
10. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15 Suppl 1:S216-227.
11. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000;283(12):1583-90.
12. Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007;23(11):2637-45.
13. D'Agostino Sr RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22(2):169-86.
14. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295(10):1152-60.
15. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010;50(12):1641-52.
16. Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003;35(1):34-9.
17. Sandberg T, Englund G, Lincoln K, Nilsson LG. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. 1990;9(5):317-23.
18. Drekonja DM, Rector TS, Cutting A, Johnson JR. Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Int Med. 2013;173(1):62-8.
19. Barza M. Anatomical barriers for antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1993;12 Suppl 1:S31-35.
20. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA. 2005;293(8):949-55.
21. Chaniotaki S, Giakouppi P, Tzouvelekis LS, Panagiotakos D, Kozanitou M, Petrikkos G, Avlami A, Vatopoulos AC. Quinolone resistance among Escherichia coli strains from community-acquired urinary tract infections in Greece. Clin Microbiol Infect. 2004;10(1):75-8.
22. Arslan H, Azap OK, Ergonul O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56(5):914-8.
23. Spellberg B, Srinivasan A, Chambers HF. New societal approaches to empowering antibiotic stewardship. JAMA. 2016;315(12):1229-30.